A multicentre, randomised, double-blind study to compare the efficacy and tolerability of dexketoprofen trometamol versus diclofenac in the symptomatic treatment of knee osteoarthritis

Clinical Drug Investigation

Volumn 19, Issue 4, 2000, Pages 247-256

  Marenco, J L ^a   Perez M ^b   Navarro, F J ^c   Martinez F G ^d   Beltran J ^e   Salvatierra, D ^f   Alonso, A ^g   Ballarin M ^h,i   Eguidazu, Isabel ^h,i,k   Zapata, A ^h,i   Horas, M ^j   Torres, F ^j   Artigas, R ^h,i   Mauleon D ^h,i  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^f HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^g HOSPITAL DE CRUCES   (Spain)

^h Dept of Pharmacology   (Italy)

ⁱ Menarini Research   (Spain)

^j UNIVERSITY OF BARCELONA   (Spain)

^k R and D Center   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTIDIABETIC AGENT; CORTICOSTEROID; COUMARIN; CYCLOSPORIN; DEXKETOPROFEN; DICLOFENAC; KETOPROFEN; LITHIUM; METHOTREXATE; PHENYTOIN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; FLATULENCE; HUMAN; KNEE OSTEOARTHRITIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; PAIN ASSESSMENT; PALLIATIVE THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; URINARY TRACT DISEASE; VOMITING;

EID: 0034007179     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019040-00002     Document Type: Article

References (34)

1. 1. Swedberg JA. Osteoarthritis. Am Fam Physician 1992; 45: 557-68
2. 2. Al Arfag A, Davis P. Osteoarthritis: current drug treatment regimens. Drugs 1991; 41 (2): 193-201
3. 3. Mauleón D, Artigas R, Garcia ML, et al. Preclinical and clinical development of dexketoprofen. Drugs 1996; 52 Suppl. 5: 24-46
4. 4. Beltrán J, Martín Mola E, Figueroa M, et al. Comparison of dexketoprofen trometamol and ketoprofen in the treatment of osteoarthritis of the knee. J Clin Pharmacol 1998; 38 Suppl. 18: 74-80
5. 5. Ezcurdia M, Cartejoso FJ, Lanzón R, et al. Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. J Clin Pharmacol 1998; 38 Suppl. 18: 65-73
6. 6. Gay C, Planas E, Donado M, et al. Analgesic effect of low doses of dexketoprofen in the dental pain model: a randomised, double-blind, placebo-controlled study. Clin Drug Invest 1996; 11: 320-30
7. 7. McGurk M, Robinson P, Rajayogeswaran V, et al. Clinical comparison of dexketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. J Clin Pharmacol 1998; 38 Suppl. 18: 46-54
8. 8. Bagán JV, López Arranz JS, Valencia E, et al. Clinical comparison of dexketoprofen trometamol and dipyrone in post-operative dental pain. J Clin Pharmacol 1998; 38 Suppl. 18: 55-64
9. 9. Veys EM. 20 years' experience with ketoprofen. Scand J Rheumatol Suppl. 1991; 90 Suppl. 1: 1-44
10. 10. Food and Drug Administration, US Department of Health and Human Services. Guidelines for the clinical evaluation of analgesic drugs. Bethesda (MD): Food and Drug Administration, 1992
11. 11. British Medical Association and the Royal Pharmaceutical Association of Great Britain. Drugs used in the treatment of musculoskeletal and joint diseases. British National Formulary (London) 1996; 31: 403-25
12. 12. European League Against Rheumatism. Guidelines for the clinical investigation of drugs used in rheumatic diseases. WHO Regional Office for Europe, Copenhagen, Denmark, March 1985
13. 13. Food and Drug Administration, US Department of Health and Human Services. Guidelines for the clinical evaluation of anti-inflammatory and antirheumatic drugs (adults and children). Bethesda (MD): Food and Drug Administration, 1988
14. 14. Lequesne MG, Mery C, Samson M, et al. Indexes of severity for osteoarthritis of the hip and knee. Validation - value in comparison with other assessment tests. Scand J Rheumatol Suppl. 1987; 65: 85-9
15. 15. Kellgren JH, Lawrence JS. Radiological assessment of osteoarthritis. Am J Rheum Dis 1957; 16: 494-501
16. 16. Bellamy N, Carette S, Ford PM. Osteoarthritis antirheumatic drug trials. I. Effects of standardization procedures on observer-dependent outcome measures. J Rheumatol 1992; 19: 436-43
17. 17. Bellamy N, Carette S, Ford PM. Osteoarthritis antirheumatic drug trials. II. Tables for calculating sample size for clinical trials. J Rheumatol 1992; 19: 444-50
18. 18. Bellamy N, Carette S, Ford PM. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials. J Rheumatol 1992; 19: 451-7
19. 19. Dupont WD. Power and sample size calculations: a review and computer program. Control Clin Trials 1990; 11: 116-28
20. 20. Carné X, Moreno V, Porta Serra M, et al. Epidemiología para clínicos: El cálculo del número de pacientes necessarios en la planificación de un estudio clínico. Med Clin (Barc) 1989; 92: 72-7
21. 21. Kantor TG, Furst DE. Osteoarthritis. In: Max MB, Portenoy RK, Laska EM, editors. Advances in pain research and therapy. New York: Raven Press, 1991: 305-15
22. 22. Caldwell J, Hutt AJ, Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-aryl-propionic acids and their biological consequences. Biochem Pharmacol 1988; 37: 105-14
23. 23. Cooper SA. Ketoprofen in oral surgery pain: a review. J Clin Pharmacol 1988; 28 (12 Suppl.): 40-6
24. 24. Hayball P, Nation RL, Bochner F. Enantioselective pharmacodynamics of the nonsteroidal antiinflammatory drug ketoprofen: in vitro inhibition of human platelet cyclooxygenase activity. Chirality 1992; 4: 484-7
25. 25. Suesa N, Fernández MF, Gutiérrez M, et al. Stereoselective cyclooxygenase inhibition in cellular models by the enantiomers of ketoprofen. Chirality 1993; 5: 589-95
26. 26. McCormack K, Urquhart E. Correlation between nonsteroidal anti-inflammatory drug efficacy in a clinical pain model and the dissociation of their anti-inflammatory and analgesic properties in animal models. Clin Drug Invest 1995; 9: 88-97
27. 27. Barbanoj MJ, Gich I, Artigas R, et al. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated doses. J Clin Pharmacol 1998; 38 Suppl. 18: 73-80
28. 28. McEwen J, De Luca M, Casini A, et al. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol 1998; 38 Suppl. 18: 41-5
29. 29. Fosslien E. Adverse effects of nonsteroidal anti-inflammatory drugs on the gastrointestinal system. Ann Clin Lab Sci 1998; 28: 67-81
30. 30. Singh G, Ramey DR. NSAID induced gastrointestinal complications: the ARAMIS perspective - 1997. J Rheumatol 1998; 25 Suppl. 51: 8-16
31. 31. Scheiman JM. NSAIDS and GI injury. Pt I. Epidemiology and pathogenesis. Drugs Today 1997; 33: 499-508
32. 32. Insel PA. Analgesic-antipyretics and antiinflammatory agents; drugs employed in the treatment of rheumatoid arthritis and gout. In: Goodman S, Gilman A, Rall T, Nies AS, et al., editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: Pergamon Press, 1990: 638-81
33. 33. Hawkey C, Kahan A, Steinbrück K, et al., International Melissa Study Group. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheumatol 1998; 37: 937-45
34. 34. Porto A, Reis C, Perdigoto B, et al. Gastroduodenal tolerability of nimesulide and diclofenac in patients with osteoarthritis. Curr Ther Res 1998; 59: 654-65